Status:

COMPLETED

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.

Lead Sponsor:

Vanderbilt-Ingram Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Postoperative Hypoparathyroidism

Thyroid Neoplasms

Eligibility:

All Genders

18-99 years

Phase:

NA

Brief Summary

This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared devic...

Detailed Description

Inadvertent damage or excision of a healthy parathyroid gland (PG) following a total thyroidectomy (TTx) could result in transient hypocalcemia (\< 6 months) in 5 - 35% of cases or permanent hypocalce...

Eligibility Criteria

Inclusion

  • (i) All patients eligible for total thyroidectomy (TTx), with or without lymph node dissection. (includes patients undergoing a TTx who have undergone a prior neck exploration for parathyroid disease or other but have an intact thyroid).
  • (ii) All patients undergoing completion thyroidectomy.

Exclusion

  • (i) Patients with concurrent parathyroid disease. (ii) Patients with incidental enlarged parathyroid discovered during TTx. (iii) Patients undergoing thyroid lobectomy/partial thyroidectomy.

Key Trial Info

Start Date :

March 16 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 23 2024

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT04281875

Start Date

March 16 2020

End Date

February 23 2024

Last Update

October 17 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37212